Selective mitochondrial uncoupler for obesity and NASH
This patent covers a new class of small-molecule drug compounds designed to selectively 'uncouple' mitochondria — essentially causing cells to burn energy as heat rather than storing it efficiently. The key innovation is selectivity: these compounds act only on mitochondria and do not disrupt the broader cell membrane potential, which is what made earlier mitochondrial uncouplers dangerously toxic. By reducing the cell's energy efficiency, the compounds also suppress reactive oxygen species, the molecular byproducts linked to aging, cancer progression, and metabolic disease. The target disease list is broad and commercially significant: obesity, type 2 diabetes, NASH/NAFLD, cancer, Parkinson's disease, and heart failure are all named.
What you could build
A small-molecule oral drug candidate targeting obesity, NASH, or type 2 diabetes, licensed to or co-developed with a mid-to-large pharmaceutical company with a metabolic disease pipeline; biotech startups building mitochondria-targeted therapeutics would also be natural acquirers.
Who in Virginia should care
Biotech and pharma companies operating near Northern Virginia or the Virginia BioTechnology Research Park in Richmond, or spinout companies from Virginia academic medical centers, would be plausible partners or licensees.
Readiness: Concept
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Webster L. Santos, Joseph Michael Salamoun, Christopher J. Garcia, Jacob H. Murray
- Filed
- Patent pending — filed July 17, 2025
- Status
- Application
- Publication number
- US20260184724A1
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.